Skip Nav Destination
Issues
1 January 2024
-
Cover Image
Cover Image
The cover shows a section of an oral squamous cell carcinoma lesion from a mouse challenged with 4-Nitroquinoline N-oxide, a tobacco-smoke carcinogen surrogate, and treated with C59, a Porcupine inhibitor. Immunohistochemical staining shows reduced non-phosphorylated (active) β-catenin expression at tumor cell borders. For details, see the article by Peña-Oyarzún and colleagues on page 209 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Sonia Singh; Diana Bradford; Xiaoxue Li; Pallavi S. Mishra-Kalyani; Yuan-Li Shen; Lingshan Wang; Hong Zhao; Ye Xiong; Jiang Liu; Rosane Charlab; Jeffrey Kraft; Sachia Khasar; Claudia P. Miller; Donna R. Rivera; Paul G. Kluetz; Richard Pazdur; Julia A. Beaver; Harpreet Singh; Martha Donoghue
Special Report
Research Briefs: Clinical Trial Brief Reports
A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia
Sandip P. Patel; Megan Othus; Young Kwang Chae; Michael J. Dennis; Sarah Gordon; David Mutch; Wolfram Samlowski; William R. “Rusty” Robinson; Elad Sharon; Christopher Ryan; Gabby Lopez; Melissa Plets; Charles Blanke; Razelle Kurzrock
Clinical Trials: Targeted Therapy
Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
Sara M. Tolaney; Shom Goel; Jorge Nadal; Hannelore Denys; Manuel R. Borrego; Lacey M. Litchfield; Jiangang Liu; Adams K. Appiah; Yanyun Chen; Fabrice André
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Yvette Drew; Jae-Weon Kim; Richard T. Penson; David M. O'Malley; Christine Parkinson; Patricia Roxburgh; Ruth Plummer; Seock-Ah Im; Martina Imbimbo; Michelle Ferguson; Ora Rosengarten; Neeltje Steeghs; Min Hwan Kim; Einav Gal-Yam; Daliah Tsoref; Jae-Hoon Kim; Benoit You; Maja De Jonge; Roy Lalisang; Eelke Gort; Sara Bastian; Kassondra Meyer; Laura Feeney; Nigel Baker; Mei-Lin Ah-See; Susan M. Domchek; Susana Banerjee; for the MEDIOLA Investigators
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Daniel P. Petrylak; Bernhard J. Eigl; Saby George; Elisabeth I. Heath; Sebastien J. Hotte; David D. Chism; Lisle M. Nabell; Joel Picus; Susanna Y. Cheng; Leonard J. Appleman; Guru P. Sonpavde; Alicia K. Morgans; Pourya Pourhosseini; Ruishan Wu; Laura Standley; Ruslan Croitoru; Evan Y. Yu
Clinical Trials: Immunotherapy
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Sarah A. Weiss; Mario Sznol; Montaser Shaheen; Miguel-Ángel Berciano-Guerrero; Eva Muñoz Couselo; Delvys Rodríguez-Abreu; Valentina Boni; Lynn M. Schuchter; Maria Gonzalez-Cao; Ana Arance; Wei Wei; Apar Kishor Ganti; Ralph J. Hauke; Alfonso Berrocal; Nicholas O. Iannotti; Frank J. Hsu; Harriet M. Kluger
Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer
Avia D. Wilkerson; Prerana Bangalore Parthasarathy; Nickolas Stabellini; Carley Mitchell; Paul G. Pavicic, Jr; Pingfu Fu; Amit Rupani; Hana Husic; Patricia A. Rayman; Shadi Swaidani; Jame Abraham; G. Thomas Budd; Halle Moore; Zahraa Al-Hilli; Jennifer S. Ko; Joseph Baar; Timothy A. Chan; Tyler Alban; C. Marcela Diaz-Montero; Alberto J. Montero
Precision Medicine and Imaging
PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax
Antoine Pinton; Lucien Courtois; Charlotte Doublet; Aurélie Cabannes-Hamy; Guillaume Andrieu; Charlotte Smith; Estelle Balducci; Agata Cieslak; Aurore Touzart; Mathieu Simonin; Véronique Lhéritier; Françoise Huguet; Marie Balsat; Hervé Dombret; Philippe Rousselot; Salvatore Spicuglia; Elizabeth Macintyre; Nicolas Boissel; Vahid Asnafi
Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma
Ankush Bhatia; Raquel Moreno; Anne S. Reiner; Subhiksha Nandakumar; Henry S. Walch; Teena M. Thomas; Philip J. Nicklin; Ye Choi; Anna Skakodub; Rachna Malani; Vivek Prabhakaran; Pallavi Tiwari; Maria Diaz; Katherine S. Panageas; Ingo K. Mellinghoff; Tejus A. Bale; Robert J. Young
Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors
Takahiro Hayashi; Kensuke Tateishi; Shinichiro Matsuyama; Hiromichi Iwashita; Yohei Miyake; Akito Oshima; Hirokuni Honma; Jo Sasame; Katsuhiro Takabayashi; Kyoka Sugino; Emi Hirata; Naoko Udaka; Yuko Matsushita; Ikuma Kato; Hiroaki Hayashi; Taishi Nakamura; Naoki Ikegaya; Yutaro Takayama; Masaki Sonoda; Chihiro Oka; Mitsuru Sato; Masataka Isoda; Miyui Kato; Kaho Uchiyama; Tamon Tanaka; Toshiki Muramatsu; Shigeta Miyake; Ryosuke Suzuki; Mutsumi Takadera; Junya Tatezuki; Junichi Ayabe; Jun Suenaga; Shigeo Matsunaga; Kosuke Miyahara; Hiroshi Manaka; Hidetoshi Murata; Takaakira Yokoyama; Yoshihide Tanaka; Takashi Shuto; Koichi Ichimura; Shingo Kato; Shoji Yamanaka; Daniel P. Cahill; Satoshi Fujii; Ganesh M. Shankar; Tetsuya Yamamoto
Comprehensive DNA Methylation Profiling of Medullary Thyroid Carcinoma: Molecular Classification, Potential Therapeutic Target, and Classifier System
Cenkai Shen; Xiao Shi; Duo Wen; Yuqing Zhang; Yuxin Du; Yu Zhang; Ben Ma; Haitao Tang; Min Yin; Naisi Huang; Tian Liao; Ting-Ting Zhang; Chang’e Kong; Wenjun Wei; Qinghai Ji; Yu Wang
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial
Juan Pablo Alderuccio; Isildinha M. Reis; Mehdi Hamadani; Muthiah Nachiappan; Salman Leslom; Brad S. Kahl; Weiyun Z. Ai; John Radford; Melhem Solh; Kirit M. Ardeshna; Brian T. Hess; Matthew A. Lunning; Pier Luigi Zinzani; Anastasios Stathis; Carmelo Carlo-Stella; Izidore S. Lossos; Paolo F. Caimi; Sunwoo Han; Fei Yang; Russ A. Kuker; Craig H. Moskowitz
A Fully Automated Deep-Learning Model for Predicting the Molecular Subtypes of Posterior Fossa Ependymomas Using T2-Weighted Images
Dan Cheng; Zhizheng Zhuo; Jiang Du; Jinyuan Weng; Chengzhou Zhang; Yunyun Duan; Ting Sun; Minghao Wu; Min Guo; Tiantian Hua; Ying Jin; Boyang Peng; Zhaohui Li; Mingwang Zhu; Maliha Imami; Chetan Bettegowda; Haris Sair; Harrison X. Bai; Frederik Barkhof; Xing Liu; Yaou Liu
Translational Cancer Mechanisms and Therapy
Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Nina Zila; Ossia M. Eichhoff; Irene Steiner; Thomas Mohr; Andrea Bileck; Phil F. Cheng; Alexander Leitner; Ludovic Gillet; Tatjana Sajic; Sandra Goetze; Betty Friedrich; Patricia Bortel; Johanna Strobl; René Reitermaier; Sabrina A. Hogan; Julia M. Martínez Gómez; Ramon Staeger; Felix Tuchmann; Sophie Peters; Georg Stary; Mario Kuttke; Adelheid Elbe-Bürger; Christoph Hoeller; Rainer Kunstfeld; Wolfgang Weninger; Bernd Wollscheid; Reinhard Dummer; Lars E. French; Christopher Gerner; Ruedi Aebersold; Mitchell P. Levesque; Verena Paulitschke
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)
Beatriz Tavira; Teresa Iscar; Luis Manso; Ana Santaballa; Marta Gil-Martin; Yolanda García García; Margarita Romeo; Maria Iglesias; Ana de Juan Ferré; María Pilar Barretina-Ginesta; Aranzazu Manzano; Lydia Gaba; María Jesús Rubio; Carlos E. de Andrea; Antonio González-Martín
FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner
Phillip M. Pifer; Liangpeng Yang; Manish Kumar; Tongxin Xie; Mitchell Frederick; Andrew Hefner; Beth Beadle; David Molkentine; Jessica Molkentine; Annika Dhawan; Mohamed Abdelhakiem; Abdullah A. Osman; Brian J. Leibowitz; Jeffrey N. Myers; Curtis R. Pickering; Vlad C. Sandulache; John Heymach; Heath D. Skinner
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
Qibiao Wu; Haley Ellis; Giulia Siravegna; Alexa G. Michel; Bryanna L. Norden; Ferran Fece de la Cruz; Eranga Roshan Balasooriya; Yuanli Zhen; Vanessa S. Silveira; Jianwe Che; Ryan B. Corcoran; Nabeel Bardeesy
Letters to the Editor
Project Confirm: Accelerated Drug Approvals for CML—Response
Kendra L. Sweet; Jorge E. Cortes; Jane F. Apperley; Mel Mann; Michael J. Mauro; Vivian G. Oehler; Cristina Ruiz; Charles A. Schiffer; Lori A. Ehrlich; Gulsum E. Pamuk; Joseph Wynne; Gautam U. Mehta; Olanrewaju O. Okusanya; R. Angelo de Claro; Marc R. Theoret; B. Douglas Smith; Kelly J. Norsworthy
Acknowledgment to Reviewers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds